Product custom-nanocomposites-lipid-nanoparticle-composite-materials

Home > products > custom-nanocomposites> lipid-nanoparticle-composite-materials

Catalog	name	Description	price
R-Mcs-557	Liposomal encapsulation polymyxin B	Liposomal encapsulation polymyxin B is a novel drug delivery system that utilizes liposome nanocarrier technology to encapsulate polymyxin B (PMB), aiming to enhance its antibacterial efficacy and reduce the nephrotoxicity and neurotoxicity of traditional formulations.	price>
R-Mcs-558	RGD-PEG-CMC-SH@Gambogic acid NPs	RGD-PEG-CMC-SH@Gambogic acid NPs/RGD-PEG-Carboxymethyl cellulose-SH@Gambogic Acid nanoparticles are a multifunctional nano delivery system that integrates active targeting, efficient drug loading, and low toxicity characteristics. The product can significantly enhance the water solubility and in vivo stability of ferulic acid, and enhance drug enrichment in tumor sites through the dual effects of EPR effect and active targeting. While reducing the systemic toxicity of ferulic acid, it fully utilizes its activity in inducing tumor cell apoptosis and inhibiting angiogenesis, providing efficient tools for precise tumor treatment and related biomedical research.	price>
R-GHLS-100NM	Calcein Liposome （100nm）	Calcein Liposome from ruixi.Compared with the aqueous solution of calcein, the liposome can greatly increase the amount of calcein in the passive transmembrane, which is mainly distributed in lysosomes. The small molecule water-soluble drugs can change the way of entering cells, improve the ability of entering cells and affect the intracellular distribution.	price>
R-R-5665	HSPC/Chol/DSPE-mPEG2000/DSPE-mPEG2000-maleimide (50/45/4/1, mol/mol) Liposomes	HSPC/Chol/DSPE-mPEG2000/DSPE-mPEG2000-maleimide (50/45/4/1, mol/mol) Liposomes. PEGylated liposomes containing free maleimide functional group for maleimide-thiol conjugation. The liposomes are co-formulated with 1 mol% DSPE-mPEG2000-maleimide, and supplied in a pH-optimized buffer for direct conjugation of the thiol-containing molecule of choice. Conjugation can be achieved by incubating the liposomes with the activated thiol-containing compound which has been reduced by a disulfide bond reducing agent such as (tris(2-carboxyethyl)phosphine) (TCEP), which can be purchased as an add-on.	price>
R-R-5666	Tanespimycin (17-AAG) Liposomes, Formulation XT28.1	Tanespimycin (17-AAG) Liposomes, Formulation XT28.1. PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.	price>
R-R-5667	DT-061 (SMAP) Liposomes, Formulation TT-40	DT-061 (SMAP) Liposomes, Formulation TT-40. PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.	price>
R-R-5668	Liposomes for Loading Hydrophobic Drugs	Liposomes for Loading Hydrophobic Drugs (5.0mL). This pre-formed liposome product is created for post loading of hydrophobic small molecule compounds into liposomes. The process of drug incorporation is very straight-forward. Then simply add an aliquot of drug solution (prepared in a water-miscible solvent such as ethanol, DMSO and etc.) into the liposome suspension. The drug molecules can be incorporated into the lipid bilayers by the nature of hydrophobic interactions. The drug solubility therefore could be significantly enhanced. Liposomal drug concentration of 1-2 mg/mL could be achieved for most lipophilic drugs. PEGylation of the liposomes provides not only better formulation stability but also the potential of achieving prolonged in vivo blood circulation. The finished drug loaded formulations are suitable for either in vitro testing or in vivo studies.	price>
R-R-5669	HSPC/CHOL (55:45 mol/mol) Liposomes with Ammonium Sulfate Gradient (100nm)	HSPC/CHOL (55:45 mol/mol) Liposomes with Ammonium Sulfate Gradient (100nm). HSPC/CHO liposomes with ammonium gradient is the formulator choice for loading of weakly basic compounds, because it offers significantly improved drug retention and the ease of use in terms of process parameters such as loading temperature (60-70 deg C). One can use this liposomes as the placebo control for the drug loaded formulation or use the much cheaper plain HSPC/CHOL liposomes as placebo control.	price>
R-R-5670	DSPC/CHOL (55:45 mol/mol) Liposomes with Ammonium Sulfate Gradient (100nm)	DSPC/CHOL (55:45 mol/mol) Liposomes with Ammonium Sulfate Gradient (100nm). DSPC/CHO liposomes with ammonium gradient is the formulator choice for loading of weakly basic compounds, because it offers significantly improved drug retention and the ease of use in terms of process parameters such as loading temperature (60-70 deg C). One can use this liposomes as the placebo control for the drug loaded formulation or use the much cheaper plain DSPC liposomes as placebo control (F10203).	price>
R-R-5671	HSPC/CHOL/mPEG2000-DSPE (50:45:5 mol/mol) Liposomes with Ammonium Sulfate Gradient (100nm)	HSPC/CHOL/mPEG-DSPE liposomes with ammonium gradient is the formulator choice in pharmaceutical/biotech industry for both formulation feasibility studies and liposomal product development, because HSPC is essentially equivalent to DSPC (HSPC contains about 85 % DSPC 15% DPPC). The main advantages for using HSPC are its lower cost and availability of GMP quality raw materials.	price>

...